JP2021523915A - 膵臓癌の治療のための化合物 - Google Patents

膵臓癌の治療のための化合物 Download PDF

Info

Publication number
JP2021523915A
JP2021523915A JP2020564201A JP2020564201A JP2021523915A JP 2021523915 A JP2021523915 A JP 2021523915A JP 2020564201 A JP2020564201 A JP 2020564201A JP 2020564201 A JP2020564201 A JP 2020564201A JP 2021523915 A JP2021523915 A JP 2021523915A
Authority
JP
Japan
Prior art keywords
compound
alkyl
another embodiment
formula
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523915A5 (https=
Inventor
リー、ウェイ
ミラー、デュエイン・ディー
チョーハン、サバッシュ
クマール カシャップ、ヴィヴェク
クマール カシャップ、ヴィヴェク
キンクイ、ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of JP2021523915A publication Critical patent/JP2021523915A/ja
Publication of JP2021523915A5 publication Critical patent/JP2021523915A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2020564201A 2018-05-15 2019-05-15 膵臓癌の治療のための化合物 Pending JP2021523915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671833P 2018-05-15 2018-05-15
US62/671,833 2018-05-15
PCT/US2019/032476 WO2019222392A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
JP2021523915A true JP2021523915A (ja) 2021-09-09
JP2021523915A5 JP2021523915A5 (https=) 2022-03-03

Family

ID=68541005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564201A Pending JP2021523915A (ja) 2018-05-15 2019-05-15 膵臓癌の治療のための化合物

Country Status (9)

Country Link
US (1) US20190374512A1 (https=)
EP (1) EP3793548A4 (https=)
JP (1) JP2021523915A (https=)
KR (1) KR20210021982A (https=)
CN (1) CN112437664A (https=)
AU (1) AU2019270091A1 (https=)
CA (1) CA3099922A1 (https=)
MX (1) MX2020012292A (https=)
WO (1) WO2019222392A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230413A1 (es) * 2020-04-03 2023-03-07 Veru Inc Metodos de tratamiento del coronavirus
CA3215936A1 (en) * 2021-04-05 2022-10-13 Veru Inc. Methods of treating inflammation
CN119212696A (zh) * 2022-04-28 2024-12-27 维鲁公司 [2-(1h-吲哚-3-基)-1h-咪唑-4-基](3,4,5-三甲氧基)甲酮和其盐的多晶型物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524422A (ja) * 2008-06-16 2011-09-01 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌を処置するための化合物
JP2013521281A (ja) * 2010-03-01 2013-06-10 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
JP2013538213A (ja) * 2010-08-24 2013-10-10 ジーティーエックス・インコーポレイテッド 癌の治療のための化合物
US20140213623A1 (en) * 2008-06-16 2014-07-31 Gtx, Inc. Compounds for treatment of cancer
JP2016510748A (ja) * 2013-03-05 2016-04-11 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524422A (ja) * 2008-06-16 2011-09-01 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌を処置するための化合物
US20140213623A1 (en) * 2008-06-16 2014-07-31 Gtx, Inc. Compounds for treatment of cancer
JP2013521281A (ja) * 2010-03-01 2013-06-10 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
JP2013538213A (ja) * 2010-08-24 2013-10-10 ジーティーエックス・インコーポレイテッド 癌の治療のための化合物
JP2016510748A (ja) * 2013-03-05 2016-04-11 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.77 (13_Supplement), JPN6022054685, 2017, pages 3216, ISSN: 0005220373 *
PHARMACEUTICAL RESEARCH, vol. 29, JPN6022054684, 2012, pages 3053 - 3063, ISSN: 0005220374 *

Also Published As

Publication number Publication date
EP3793548A4 (en) 2022-03-09
AU2019270091A1 (en) 2020-12-24
WO2019222392A1 (en) 2019-11-21
EP3793548A1 (en) 2021-03-24
KR20210021982A (ko) 2021-03-02
CN112437664A (zh) 2021-03-02
CA3099922A1 (en) 2019-11-21
US20190374512A1 (en) 2019-12-12
MX2020012292A (es) 2021-03-29

Similar Documents

Publication Publication Date Title
JP6835472B2 (ja) 癌の処置のための組成物
JP7114745B2 (ja) トリプルネガティブ乳癌および卵巣癌の治療のための化合物
JP5879273B2 (ja) 癌を処置するための化合物
CN110475554B (zh) 用于预防或治疗靶向鞘氨醇1-磷酸受体4的非酒精性脂肪性肝炎的组合物
KR102452370B1 (ko) 신경교종을 포함하는 암을 치료하기 위해 에플로르니틴 및 이의 유도체 및 동족체를 사용하기 위한 조성물 및 방법
JP2010168387A (ja) マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
JP7197370B2 (ja) がんの予防および／または治療のための化合物、組成物および方法
CN110785170B (zh) 脂肪细胞的治疗
JP2021523915A (ja) 膵臓癌の治療のための化合物
JP7237383B2 (ja) アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤
JP2014509608A (ja) 前立腺癌を治療するための、抗クラステリンオリゴヌクレオチドとｈｓｐ９０阻害剤との併用
KR102382771B1 (ko) 증식성 질환을 위한 조합 치료
KR20130061684A (ko) 비뇨기 동통을 수반하는 질환의 예방 또는 치료제
HK40043322A (en) Compounds for treatment of pancreatic cancer
RU2776897C2 (ru) Соединения для лечения трижды негативного рака молочной железы и рака яичника
HK40043706A (en) Compounds for treatment of triple negative breast cancer and ovarian cancer
HK40007875A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
HK40007875B (en) Compounds, compositions and methods for prevention and/or treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231208

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231222